Nikita Kotlov
Overview
Explore the profile of Nikita Kotlov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turova P, Kushnarev V, Baranov O, Butusova A, Menshikova S, Yong S, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):19.
PMID: 39979291
Current breast cancer classification methods, particularly immunohistochemistry and PAM50, face challenges in accurately characterizing the HER2-low subtype, a therapeutically relevant entity with distinct biological features. This notable gap can lead...
2.
Tumuluru S, Godfrey J, Cooper A, Yu J, Chen X, MacNabb B, et al.
Blood
. 2025 Jan;
PMID: 39869833
Most diffuse large B-cell lymphoma (DLBCL) patients treated with immunotherapies such as bispecific antibodies (BsAb) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the...
3.
Nikitina A, Kiriy D, Tyshevich A, Tychinin D, Antysheva Z, Sobol A, et al.
Viruses
. 2025 Jan;
17(1).
PMID: 39861794
Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HPV-positive HNSCC) has distinct biological characteristics from HPV-negative HNSCC. Using an AI-based analytical platform on meta cohorts, we profiled expression patterns...
4.
Yang J, Cali Daylan A, Shevkoplias A, Postovalova E, Wang M, Tyshevich A, et al.
Cells
. 2025 Jan;
14(2).
PMID: 39851562
Kaposi Sarcoma (KS) is a vascular tumor originating from endothelial cells and is associated with human herpesvirus 8 (KSHV) infection. It disproportionately affects populations facing health disparities. Although antiretroviral therapy...
5.
Horwitz S, Nirmal A, Rahman J, Xu R, Drill E, Galasso N, et al.
Nat Med
. 2024 Nov;
30(12):3778.
PMID: 39548313
No abstract available.
6.
Horwitz S, Nirmal A, Rahman J, Xu R, Drill E, Galasso N, et al.
Nat Med
. 2024 Jun;
30(9):2517-2527.
PMID: 38886623
PI3K-δ inhibitors have shown impressive activity in lymphoid malignancies but have been hampered by autoimmune and infectious toxicities, leading to market withdrawals. We previously demonstrated activity of the PI3K-δγ inhibitor...
7.
Kotlov N, Shaposhnikov K, Tazearslan C, Chasse M, Baisangurov A, Podsvirova S, et al.
Commun Biol
. 2024 Mar;
7(1):392.
PMID: 38555407
With the increased use of gene expression profiling for personalized oncology, optimized RNA sequencing (RNA-seq) protocols and algorithms are necessary to provide comparable expression measurements between exome capture (EC)-based and...
8.
Radtke A, Postovalova E, Varlamova A, Bagaev A, Sorokina M, Kudryashova O, et al.
Cancer Cell
. 2024 Mar;
42(3):444-463.e10.
PMID: 38428410
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic...
9.
Tumuluru S, Godfrey J, Cooper A, Yu J, Chen X, MacNabb B, et al.
bioRxiv
. 2024 Feb;
PMID: 38328071
Most diffuse large B-cell lymphoma (DLBCL) patients treated with bispecific antibodies (BsAb) or chimeric antigen receptor (CAR) T cells fail to achieve durable treatment responses, underscoring the need for a...
10.
Al Assaad M, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, et al.
Front Oncol
. 2024 Feb;
13:1274163.
PMID: 38318324
Cancer of unknown primary (CUP) represents a significant diagnostic and therapeutic challenge, being the third to fourth leading cause of cancer death, despite advances in diagnostic tools. This article presents...